Volt™ PFA System simplifies therapy delivery, minimizing procedural burden so you can treat more patients with ease and precision.1*
Delivers targeted lesion sets where it matters with an 8-spline balloon-in-basket design that conforms to anatomy and creates a wide-band lesion2 for fewer repositions
Gain real-time procedural insight with elegant impedance-based contact visualization through AutoMark and eField integration for precise lesion tracking3,4
Three handling options for optimal positioning
Ensures ease of use and adaptability with an intuitive generator – designed for now and the future
Current™ PFA Generator is designed to minimize microbubbles5 and patient movement for stability during energy delivery2
The only standalone generator with an integrated tissue contact display – empowering contact-guided energy applications, with or without a mapping system4
Features distal and proximal magnetic sensors for seamless EnSite™ X EP System integration
Eliminates the need for general anesthesia through light sedation compatibility6
Subjects under conscious sedation (CS) and deep sedation (DS) workflows experienced acute effectiveness with no significant difference in safety when compared to general anesthesia (GA) procedures.6,14
Create PVI with as few as two applications per vein1
The lowest number of applications of any PFA tool1 minimizing catheter repositions and increasing procedural efficiency1
*Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
Customize therapy for anatomic and patient variation by selectively delivering energy from electrodes in good contact
Enable a single-catheter workflow for mapping, pacing and ablating, minimizing catheter exchanges
Protocol required PVI only left atrial ablation with the Volt™ PFA System
In multiple analyses, no clinically relevant hemolysis was observed, and biomarkers did not exhibit statistically significant change.11-13
Volt PFA System directly targets tissue, avoiding the blood pool, and removes the need for additional fluid.11
No periprocedural hydration protocol performed
Applications per patient: 17.7 ± 3.8 PFA applications/subject
Non-significant changes in hemolysis biomarkers and renal function in 157 subjects across 27 sites13
Volt is commercially available in Europe.
Caution - This product is limited by US Federal law to investigational use. Product is not approved globally.
* Faster procedures allows us to treat more patients.
** In listed CE Mark or IDE trials for acheivement of PVI.
† 4 veins in 1 subject did not have assessment after 20 min wait period.
MAT-2502382 v3.0
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0
